Loading stocks --

← Corporate Announcements

OTHER SEARL The Searle Company Limited

The Searle Company Limited (SEARL) Corporate Briefing Session: Company highlights strong FY2026 financial performance.

Stock ImpactPositive
The Searle Company Limited (SEARL)
Corporate Briefing Session - FY 2026

The Searle Company Limited conducted its Corporate Briefing Session for FY 2026, highlighting robust financial recovery and a diversified business platform across the IBL Group.

Key Highlights
  • Strong Revenue Growth: Standalone Sales reached PKR 31.64bn in FY 2026, a 28% increase YoY.
  • Profitability Turnaround: Standalone Profit After Tax (PAT) improved significantly to PKR 4.00bn compared to PKR 434mn in FY 2025.
  • Market Leadership: Fourth largest pharmaceutical company in Pakistan by units sold; over 500,000 daily prescriptions.
  • Diversified Footprint: Operates in 16 therapeutic areas with 6 state-of-the-art manufacturing plants.
  • Product Pipeline: Significant focus on new launches across pharmaceuticals, nutraceuticals, and medical devices.

Strategic Outlook

Management emphasized brand leadership in key therapeutic areas like Cardiovascular, Gynae, and Cough, with a focus on margin expansion and financial health improvement.

Disclaimer: This summary is based on the provided corporate briefing presentation. No new dividend or corporate entitlement was declared in this filing.

PSX Data Portal

Financial results — 19 Nov 2026

No financial results today — showing the last working day with results.